Frederick S Stinson1, W June Ruan, Roger Pickering, Bridget F Grant. 1. Laboratory of Epidemiology and Biometry, Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892-9304, USA.
Abstract
BACKGROUND: The purpose of this study was to present 12-month and lifetime estimates of the prevalence, sociodemographic and clinical correlates, and psychiatric co-morbidity of DSM-IV cannabis abuse and dependence. METHOD: Data were derived from a large nationally representative survey (n=43093) of US adults. RESULTS: The prevalence of 12-month and lifetime DSM-IV cannabis abuse (1.1% and 7.2%) exceeded the corresponding rates of cannabis dependence (0.3% and 1.3%). Being male, Native American, widowed/separated/divorced, and residing in the West increased the odds whereas being Black, Asian or Hispanic decreased the odds of cannabis abuse and dependence. Cannabis dependence was significantly associated with low income. Ages of onset for both cannabis use disorders occurred in adolescence and the majority of individuals with these disorders remained untreated. Co-morbidity was high between cannabis use disorders and other Axis I and II disorders. CONCLUSIONS: Cannabis use disorders continue to present a widespread and serious personal and public health problem. Native Americans were found to have high rates of cannabis use disorders, warranting closer attention to the mental health needs of this subgroup. Associations between cannabis abuse and dependence and Axis I and II disorders were strong, signaling the need for more comprehensive assessment of individuals with cannabis use disorders. Further controlled treatment studies are needed, especially among co-morbid individuals, in view of growing evidence of the adverse personal, medical and societal impacts of cannabis use disorders in the USA.
BACKGROUND: The purpose of this study was to present 12-month and lifetime estimates of the prevalence, sociodemographic and clinical correlates, and psychiatric co-morbidity of DSM-IV cannabis abuse and dependence. METHOD: Data were derived from a large nationally representative survey (n=43093) of US adults. RESULTS: The prevalence of 12-month and lifetime DSM-IV cannabis abuse (1.1% and 7.2%) exceeded the corresponding rates of cannabis dependence (0.3% and 1.3%). Being male, Native American, widowed/separated/divorced, and residing in the West increased the odds whereas being Black, Asian or Hispanic decreased the odds of cannabis abuse and dependence. Cannabis dependence was significantly associated with low income. Ages of onset for both cannabis use disorders occurred in adolescence and the majority of individuals with these disorders remained untreated. Co-morbidity was high between cannabis use disorders and other Axis I and II disorders. CONCLUSIONS: Cannabis use disorders continue to present a widespread and serious personal and public health problem. Native Americans were found to have high rates of cannabis use disorders, warranting closer attention to the mental health needs of this subgroup. Associations between cannabis abuse and dependence and Axis I and II disorders were strong, signaling the need for more comprehensive assessment of individuals with cannabis use disorders. Further controlled treatment studies are needed, especially among co-morbid individuals, in view of growing evidence of the adverse personal, medical and societal impacts of cannabis use disorders in the USA.
Authors: Carla J Berg; Carmen N Daniel; Milkie Vu; Jingjing Li; Kathleen Martin; Lana Le Journal: Subst Use Misuse Date: 2017-08-04 Impact factor: 2.164
Authors: Julia D Buckner; Richard G Heimberg; Franklin R Schneier; Shang-Min Liu; Shuai Wang; Carlos Blanco Journal: Drug Alcohol Depend Date: 2012-01-21 Impact factor: 4.492
Authors: Bradley T Kerridge; Tulshi D Saha; S Patricia Chou; Haitao Zhang; Jeesun Jung; W June Ruan; Sharon M Smith; Boji Huang; Deborah S Hasin Journal: Drug Alcohol Depend Date: 2015-09-02 Impact factor: 4.492
Authors: Anne Campbell; Steffani R Bailey; Kim A Hoffman; Javier Ponce-Terashima; Katie Fankhauser; Miguel Marino; Dennis McCarty Journal: J Psychoactive Drugs Date: 2020-04-15
Authors: Ian R Gizer; David A Gilder; Philip Lau; Ting Wang; Kirk C Wilhelmsen; Cindy L Ehlers Journal: J Stud Alcohol Drugs Date: 2013-03 Impact factor: 2.582
Authors: Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese K Killeen; Amanda M Wagner; Kathleen T Brady; C Lindsay DeVane; Jessica Norton Journal: Drug Alcohol Depend Date: 2015-08-25 Impact factor: 4.492
Authors: Daniel Fuster; Debbie M Cheng; Donald Allensworth-Davies; Tibor P Palfai; Jeffrey H Samet; Richard Saitz Journal: J Gen Intern Med Date: 2013-09-19 Impact factor: 5.128